Get to know our clinical trials

Clinical trial to investigate how people with advanced cancer (solid tumors) tolerate different doses of BI 3820768.

PHASE I STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF BI 3820768 IN PATIENTS WITH ADVANCED, RELAPSED, OR TREATMENT-REFRACTORY GERM CELL TUMORS, ENDOMETRIAL CANCER, OR OVARIAN CANCER.

Imagen del Dr. Antonio González Martín, director del Departamento de Oncología Médica de la Clínica Universidad de Navarra
Dr. Antonio González Curriculum
Director Medical Oncology Department
Madrid headquarters
Cancer Center
Gynecologic Cancer Area
Status
In recruitment
headquarters
Madrid
Early phase

Technical Summary

  • PHASE I STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF BI 3820768 IN PATIENTS WITH ADVANCED, RELAPSED, OR TREATMENT-REFRACTORY GERM CELL TUMORS, ENDOMETRIAL CANCER, OR OVARIAN CANCER.
  • Code EudraCT: 2025-522913-45-00
  • Protocol number: 2001-0001
  • Promoter: Boehringer Ingelheim España, S.A.
  • Molecule/Drug: BI 3820768
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION